Innate Immune Cell Phenotypes and Early Fibrotic Repair in Acute Myocardial Infarction

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07764588

Acronym

ICE-AMI

Enrollment

Registered

2026-08-14

Start date

2026-01-01

Completion date

2026-12-31

Last updated

2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Keywords

neutrophil, monocyte, myocardial infarction, cardiac remodeling, cardiac magnetic resonance

Brief summary

To determine the relationship of the phenotypes of neutrophils and monocytes with early fibrotic repair after acute myocardial infarction.

Detailed description

This study will enroll 50 patients with ST-segment elevation myocardial infarction (STEMI). Peripheral blood will be collected from these patients for immune cell subset analysis, serum cytokine evaluation, and neutrophil sorting for transcriptome sequencing. At 1 week after admission, cardiac magnetic resonance (CMR) will be performed to evaluate the myocardial salvage index, area of late gadolinium enhancement (LGE), microvascular obstruction (MVO), extracellular volume (ECV), and left ventricular ejection fraction (LVEF).

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

\---- Age \> 18 and ≤ 80 years old \- Patients with acute STEMI within 12 hours of symptom onset who are planned to receive PPCI

Exclusion criteria

* Prior revascularization * Known allergy to gadopentetate dimeglumine contrast agent * Pregnancy or planned pregnancy within the next 6 months * Life expectancy \< 1 year * Metallic implants or claustrophobia that precluded MRI * Severe COPD or inability to hold breath for MRI * Severe hepatic or renal dysfunction (ALT \> 5×ULN or eGFR \< 15 mL/min/1.73 m²)

Design outcomes

Primary

Measure	Time frame	Description
Major cardiac adverse outcome	At 12 months after enrollment	The composite endpoint included cardiac death, non-fatal myocardial infarction, and rehospitalization for angina.

Secondary

Measure	Time frame	Description
Cardiac remodeling measured by CMR	At 1 week after admission	CMR will be performed to evaluate the cardiac fibrosis defined as area of late gadolinium enhancement (LGE).

Countries

China

Contacts

CONTACTJianhui Zhuang, MD

jh_zhuang@tongji.edu.cn86-13621742833

Outcome results